Source: Annual Congress 2013 –Biological signatures in thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Tsao (Toronto, Canada). Can genomic signatures predict response to systemic therapy?. Annual Congress 2013 –Biological signatures in thoracic oncology

Member's Comments

No comment yet.

Related content which might interest you: A change in blood transcriptional signatures accompanies successful tuberculosis therapy Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012 TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Can intermediate monocytes predict response to infliximab therapy in sarcoidosis? Source: Eur Respir J 2016; 48: 1242-1245 Year: 2016 How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …? Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets? Year: 2019 A sputum gene expression signature predicts oral corticosteroid response in asthma Source: Eur Respir J, 49 (6) 1700180; 10.1183/13993003.00180-2017 Year: 2017 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA). Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 The influence of TNFα gene polymorphism on the therapeutic response in patients with sarcoidosis Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 The microbiome, cancer development and response to therapy Source: International Congress 2018 – Scientific Year in Review Year: 2018 Does lung function predict response to therapy in PAH associated with connective tissue disease? Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Does a predominant clinical COPD phenotype predict different outcome responses to pulmonary rehabilitation? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? Source: ERJ Open Res, 4 (4) 00030-2018; 10.1183/23120541.00030-2018 Year: 2018 The future of targeted therapies for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 COPD phenotypes and co-morbidities: to what extent do they affect a successful response to rehabilitation? Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011